The Effectiveness of Intensity Modulated Radiation Therapy Versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 May 13

PMID 27171271

Citations 33

Authors

Ting Yu

Qiongwen Zhang

Tianying Zheng

Huashan Shi

Yang Liu

Shijian Feng

Meiqin Hao

Lei Ye

Xueqian Wu

Cheng Yang

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Intensity modulated radiation therapy (IMRT) can deliver higher doses with less damage of healthy tissues compared with three-dimensional radiation therapy (3DCRT). However, for the scenarios with better clinical outcomes for IMRT than 3DCRT in prostate cancer, the results remain ambiguous. We performed a meta-analysis to assess whether IMRT can provide better clinical outcomes in comparison with 3DCRT in patients diagnosed with prostate cancer.

Materials And Methods: We conducted a meta-analysis of 23 studies (n = 9556) comparing the clinical outcomes, including gastrointestinal (GI) toxicity, genitourinary (GU) toxicity, biochemical controland overall survival (OS).

Results: IMRT was significantly associated with decreased 2-4 grade acute GI toxicity [risk ratio (RR) = 0.59 (95% confidence interval (CI), 0.44, 0.78)], late GI toxicity [RR = 0.54, 95%CI (0.38, 0.78)], late rectal bleeding [RR = 0.48, 95%CI (0.27, 0.85)], and achieved better biochemical control[RR = 1.17, 95%CI (1.08, 1.27)] in comparison with 3DCRT. IMRT and 3DCRT remain the same in regard of grade 2-4 acute rectal toxicity [RR = 1.03, 95%CI (0.45, 2.36)], late GU toxicity [RR = 1.03, 95%CI (0.82, 1.30)] and overall survival [RR = 1.07, 95%CI (0.96, 1.19)], while IMRT slightly increased the morbidity of grade 2-4 acute GU toxicity [RR = 1.08, 95%CI (1.00, 1.17)].

Conclusions: Although some bias cannot be ignored, IMRT appears to be a better choice for the treatment of prostate cancer when compared with 3DCRT.

Citing Articles

Evaluating the Predictive Value of the Dose-volume Parameters and Vascular Endothelial Growth Factor Expression on Rectal Toxicity in Prostate Cancer Patients.

Mirzaeiyan M, Khanahmad H, Hemati S, Etehadtavakol M, Sharifonnasabi Z, Shokrani P J Med Phys. 2025; 49(4):539-544.

PMID: 39926150 PMC: 11801083. DOI: 10.4103/jmp.jmp_67_24.

Comparing post-treatment urinary and colorectal procedures in prostate cancer patients using population-based linked data.

Tiruye T, Jay A, Higgs B, OCallaghan M, FitzGerald L, Moretti K Int Urol Nephrol. 2024; 57(4):1189-1198.

PMID: 39658770 DOI: 10.1007/s11255-024-04304-1.

Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations.

Stanberry B, Webber-Jones N Prostate Cancer Prostatic Dis. 2024; 28(1):23-36.

PMID: 38480973 DOI: 10.1038/s41391-024-00817-z.

Clinical and functional outcomes for risk-appropriate treatments for prostate cancer.

Tiruye T, OCallaghan M, Ettridge K, Moretti K, Jay A, Higgs B BJUI Compass. 2024; 5(1):109-120.

PMID: 38179028 PMC: 10764171. DOI: 10.1002/bco2.288.

Gastrointestinal/genitourinary adverse event after intensity modulated versus three-dimensional primary radiation therapy in the treatment of prostate cancer: systematic review and meta-analysis.

Guo W, Sun Y, Zhang L, Yin X J Cancer. 2023; 14(15):2878-2888.

PMID: 37781069 PMC: 10539562. DOI: 10.7150/jca.87626.

References

Lawton C, Won M, Pilepich M, Asbell S, Shipley W, Hanks G . Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991; 21(4):935-9. DOI: 10.1016/0360-3016(91)90732-j. View

Pollack A, Zagars G, Starkschall G, Antolak J, Lee J, Huang E . Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53(5):1097-105. DOI: 10.1016/s0360-3016(02)02829-8. View

Phan J, Swanson D, Levy L, Kudchadker R, Bruno T, Frank S . Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management. Cancer. 2009; 115(9):1827-39. DOI: 10.1002/cncr.24223. View

Ashman J, Zelefsky M, Hunt M, Leibel S, Fuks Z . Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 63(3):765-71. DOI: 10.1016/j.ijrobp.2005.02.050. View

Kramer K, Bennett C, Pickard A, Lyons E, Wolf M, McKoy J . Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer. 2005; 4(1):15-23. DOI: 10.3816/cgc.2005.n.007. View

Beckendorf V, Guerif S, Le Prise E, Cosset J, Bougnoux A, Chauvet B . 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2010; 80(4):1056-63. DOI: 10.1016/j.ijrobp.2010.03.049. View

Michalski J, Winter K, Purdy J, Parliament M, Wong H, Perez C . Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005; 62(3):706-13. DOI: 10.1016/j.ijrobp.2004.11.028. View

Daskivich T, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A . Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117(10):2058-66. DOI: 10.1002/cncr.25751. View

Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, Sefrova J . Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia. Int J Urol. 2010; 17(9):784-90. DOI: 10.1111/j.1442-2042.2010.02592.x. View

10.

Haas G, Barry Delongchamps N, Jones R, Chandan V, Serio A, Vickers A . Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007; 99(19):1484-9. DOI: 10.1093/jnci/djm153. View

11.

Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo G . IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol. 2009; 93(2):207-12. DOI: 10.1016/j.radonc.2009.08.042. View

12.

Staffurth J . A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2010; 22(8):643-57. DOI: 10.1016/j.clon.2010.06.013. View

13.

Lee N, Puri D, Blanco A, Chao K . Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck. 2005; 29(4):387-400. DOI: 10.1002/hed.20332. View

14.

Ohri N, Dicker A, Showalter T . Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol. 2012; 19(4):6373-80. PMC: 3808959. View

15.

Damast S, Wolden S, Lee N . Marginal recurrences after selective targeting with intensity-modulated radiotherapy for oral tongue cancer. Head Neck. 2011; 34(6):900-6. DOI: 10.1002/hed.21677. View

16.

Bednarz B, Athar B, Xu X . A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models. Med Phys. 2010; 37(5):1987-94. PMC: 2862056. DOI: 10.1118/1.3367012. View

17.

Sharma N, Li T, Chen D, Pollack A, Horwitz E, Buyyounouski M . Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2010; 69(3):S10. PMC: 2909627. DOI: 10.1016/j.ijrobp.2007.07.019. View

18.

Hanks G . Conformal radiotherapy for prostate cancer. Ann Med. 2000; 32(1):57-63. DOI: 10.3109/07853890008995911. View

19.

Fiveash J, Hanks G, Roach M, Wang S, Vigneault E, McLaughlin P . 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys. 2000; 47(2):335-42. DOI: 10.1016/s0360-3016(00)00441-7. View

20.

Marta G, Silva V, Carvalho H, Freire de Arruda F, Hanna S, Gadia R . Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2013; 110(1):9-15. DOI: 10.1016/j.radonc.2013.11.010. View